Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS2940 in solid tumors with EGFR/HER2 aberrations
NCT04982926Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Sep 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of TAS2940 in non-small cell lung cancer (NSCLC), breast cancer, glioblastoma (GBM) and 1 more (5 arms), sponsored by Taiho Oncology. Primary endpoints: Maximum Tolerated Dose at 1 month and Overall Response Rate at 6 months. Started Sep 2021; status: terminated.
02
Drugs
TAS2940
03
Conditions
non-small cell lung cancer (NSCLC)breast cancerglioblastoma (GBM)solid tumor
Beyond the preview
Go deeper on NCT04982926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982926.